Pearl Therapeutics named Chuck Bramlage, former president of pharmaceutical products for Covidien plc, as president and CEO.
Bramlage replaces Howard Rosen, who filled in after Perry Karsen's return late last summer to Celgene Corp. Rosen will return to Pearl’s board.
No comments:
Post a Comment